- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
FDA approves Colazal for pediatric patients
In December, the U.S. Food and Drug Administration (FDA) approved the use of Zolazal (balsalazide disodium) capsules 750 mg in pediatric patients between 5 to 17 years of age with ulcerative colitis. Colazal, an anti-inflammatory drug approved for the treatment of mildly to moderately active ulverative colitis, is manufactured by Salix Pharmaceuticals, Ltd.
In December, the U.S. Food and Drug Administration (FDA) approved the use of Zolazal (balsalazide disodium) capsules 750 mg in pediatric patients between 5 to 17 years of age with ulcerative colitis. Colazal, an anti-inflammatory drug approved for the treatment of mildly to moderately active ulverative colitis, is manufactured by Salix Pharmaceuticals, Ltd.
"We believe this approval speaks, in large part, to the tolerability of our unique, ago-bonded pro drug formulation of 5-ASA, which is specifically designed for 99% delivery of 5-ASA directly to the colon," commented Carolyn Logan, Salix Pharmaceuticals' president and c.e.o. "This approval, combined with the September labeling approval which provides for the administration of Colazal as sprinkled over applesauce, should provide gastroenterologists with an option that increases their level of comfort and confidence in treating children."
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
